However, first-line combination treatment with erlotinib and bevacizumab was shown to significantly improve PFS over erlotinib alone in patients with EGFR mutation-positive NSCLC [24], and such combinations of EGFR tyrosine kinase inhibitors with VEGF-targeting antibodies are in clinical development for molecularly defined subpopulations of lung cancer patients. The gene discussed is EGFR; the disease is lung cancer.